Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
RARE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.81 - $60.37
Previous CloseN/A
Volume75.38K
Average Volume (3M)2.20M
Market Cap
$2.82B
Enterprise Value$3.97B
Total Cash (Recent Filing)$496.62M
Total Debt (Recent Filing)$882.91M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 04, 2025EPS Estimate
-1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding96,371,640
10 Day Avg. Volume1,379,767
30 Day Avg. Volume2,197,975
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.41
Enterprise Value/Revenue6.51
Enterprise Value/Gross Profit7.76
Enterprise Value/Ebitda-9.13
Forecast
1Y Price Target
$84.38Price Target Upside185.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Bulls Say, Bears Say
Bulls Say
Pipeline And Commercial MomentumThe Overweight rating on RARE shares is based on a positive outlook on setrusumab, an underappreciated pipeline, and ongoing commercial momentum.
Potential Market OpportunityConsidering the significant burden of disease, including the requirement to ingest large quantities of cornstarch multiple times each day, a treatment that can reduce this burden would be well received by the community.
Regulatory ProgressUltragenyx has initiated the rolling submission of the BLA for DTX401 in Glycogen Storage Disease Type Ia, which may begin to get more credit as it progresses towards commercialization.
Bears Say
Investor ConcernsUltragenyx shares have been under pressure due to investor disappointment in the interim readout from the pivotal Orbit trial of UX143 (setrusumab) in osteogenesis imperfecta (OI).
Regulatory DelaysThe BLA submission for DTX401 for GSD1a has been delayed to the fourth quarter of 2025.
Stock Valuation ConcernsDespite the continued growth in the base business, the stock is trading at <$30/share, which is below what the commercial business is worth, with seemingly zero value ascribed to the pipeline.
Ultragenyx Pharmaceutical News
RARE FAQ
What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was $25.81 and its highest was $60.37 in the past 12 months.
What is Ultragenyx Pharmaceutical’s market cap?
Ultragenyx Pharmaceutical’s market cap is $2.82B.
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s upcoming earnings report date is Nov 04, 2025 which is in 68 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on Aug 05, 2025. The company reported -$1.17 earnings per share for the quarter, beating the consensus estimate of -$1.297 by $0.127.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is -1.23.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 96,371,640 shares outstanding.
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -$1.17 in its last earnings report, beating expectations of -$1.297. Following the earnings report the stock price went down -3.008%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Currently, no hedge funds are holding shares in RARE
Ultragenyx Pharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$84.38 (185.45% Upside)
$84.38 (185.45% Upside)
Blogger Sentiment
Bullish
RARE Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $89.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 11.0%
Last 30 Days ▲ 11.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.42%
12-Months-Change
Fundamentals
Return on Equity
-182.60%
Trailing 12-Months
Asset Growth
-19.29%
Trailing 12-Months
Company Description
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
RARE Company Deck
RARE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Ultragenyx's earnings call showcased significant achievements, including program approvals, Breakthrough Therapy designation, and strong revenue growth. However, challenges such as delays in BLA submissions and financial losses were also highlighted.View all RARE earnings summariesRARE Stock 12 Month Forecast
Average Price Target
$84.38
▲(185.45% Upside)
Technical Analysis
PTC Therapeutics
―
Crispr Therapeutics AG
―
Zai Lab
―
Springworks Therapeutics
―
Arcellx Inc
―
Ownership Overview
4.01% Insiders
26.84% Mutual Funds
41.71% Other Institutional Investors
13.44% Public Companies and Individual Investors